Page 112 - Educacional Ponenecias Congreso SEHH-STH 2020

12. Kahl BS,Hamadani M,Radford J,Carlo-Stella C,Caimi P,Reid E,et al.A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine- Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2019;25:6986-94.
13. Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. J Clin Oncol. 2016;34:1104-11.
14. Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al . Phase 2study of the bispecific T-cell engager (BiTE) antibody blinatu- momab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016 Mar 17;127(11):1410-6.
15. Budde LE, Sehn LH, Assouline S, Flinn IW, Isufi I, Yoon SS, et al. Mosunetu- zumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non- Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood. 2018;132:399.
16. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698-704.
17. Ansell SM,Minnema MC,Johnson P,Timmerman JM,Armand P,Shipp MA,et al. Nivolumab for relapsed/refractory diffuse large b-cell lymphoma in pa- tients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481-9.
18. Kline J, Godfrey J, Ansell SM. The immune landscape and response to im- mune checkpoint blockade therapy in lymphoma. Blood. 2020;135:523-33.
19. Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refrac-
tory primary mediastinal large B-cell lymphoma. Blood. 2017;130:267-70.
20. Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071-3.
21. Tilly H, Gomes da Silva M, Vitolo U. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:116-25.
22. Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M; Euro- pean Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chime- ric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Trans- plantation? Biol Blood Marrow Transplant. 2020;26:e77-e85.
23. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lym- phoma. N Engl J Med. 2017;377:2531-44.
24. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lym- phoma. N Engl J Med. 2019;380:45-56.
25. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, et al. Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood. 2019;134:241a.
26. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard- of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 May 13:JCO1902104.
27. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372-85.
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
112